OncoCyte Corporation (OCX)
NASDAQ: OCX · IEX Real-Time Price · USD
3.210
+0.090 (2.88%)
At close: Jul 19, 2024, 4:00 PM
3.130
-0.080 (-2.49%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
OncoCyte Employees
As of December 31, 2023, OncoCyte had 46 total employees, including 43 full-time and 3 part-time employees. The number of employees decreased by 30 or -39.47% compared to the previous year.
Employees
46
Change (1Y)
-30
Growth (1Y)
-39.47%
Revenue / Employee
$30,043
Profits / Employee
-$888,283
Market Cap
42.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
Fortress Biotech | 186 |
Owlet | 76 |
BioXcel Therapeutics | 74 |
Envoy Medical | 34 |
Movano | 30 |
Tempest Therapeutics | 17 |
Dyadic International | 7 |
OCX News
- 27 days ago - Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move - GlobeNewsWire
- 7 weeks ago - Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine - GlobeNewsWire
- 2 months ago - Oncocyte Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Oncocyte Reports Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients - GlobeNewsWire
- 1 year ago - Oncocyte Announces 1-For-20 Reverse Stock Split - GlobeNewsWire
- 1 year ago - Oncocyte Begins Manufacturing Transplant Blood Test - GlobeNewsWire